- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02073838
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
A Phase II, Multi-center, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T1E2
- Jewish General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA
- Patients with AML M4 or M5 FAB subtype or high eIF4E are eligible.
- All patients must have failed primary therapy (defined as two induction chemotherapies), must have relapsed, or must not be suitable candidates for intensive induction chemotherapy.
- Patients who have a dry aspirate or extramedullary disease only are eligible for this study if they have a pre-treatment marrow or tissue biopsy demonstrating AML M4 or M5 subtype or high eIF4E.
- ECOG performance status 0, 1, 2.
- Life expectancy>4 weeks.
- Age is > 18 years.
Female patients of childbearing potential (FCBP) is defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy, or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). In addition, women under the age of 55 years must have a serum follicle stimulating hormone (FSH) level > 40IU/L to confirm menopause.
FCBP must have a negative serum (beta-HCG) pregnancy test (minimum sensitivity 25 IU/L of equivalent units of HCG) within 7 days of starting treatment and must not be breastfeeding. Men and females of childbearing potential must agree to use two effective means of contraception, with one method being highly effective and the other method being either highly effective or less effective as listed below throughout the study and for at least 24 months after completion of protocol.
An effective means of contraception includes the following:
i. Male condoms with spermicide ii. Hormonal methods of contraception including combined oral contraception pills, vaginal ring, injectables, implants, and intrauterine devices (IUDs).
iii. Nonhormonal IUDs iv. Tubal ligation v. Vasectomy vi. Complete Abstinence
A less effective means of contraception includes the following:
i. Diaphragm with spermicide ii. Vaginal sponge iii. Male condom without spermicide iv. Progestin only pills by females of childbearing potential or male subject's FCBP partners v. Female condom (a male and female condom must not be used together)
Male subjects must not donate semen while on study and during 24 months after treatment discontinuation.
- Adequate renal and hepatic function: serum creatinine < 1.5 x ULN; AST or ALT < 2.5 x ULN (or < 5 x ULN if liver involvement with leukemia); serum bilirubin < 1.5 x ULN
- Provide written consent after the investigational nature, study design, risks and benefits of the study have been explained.
- Accessible for treatment and follow up.
EXCLUSION CRITERIA
- Patients with impaired ribavirin uptake. As tested in the central laboratory.
- Uncontrolled central nervous system involvement by AML.
- Active cardiovascular disease as defined by New York Heart Association (NYHA) class III-IV categorization.
- Patients with hemoglobinopathies which may affect their ability to tolerate ribavirin.
- Intercurrent illness or medical condition precluding safe administration of the planned protocol treatment or required follow-up.
- Received any previous therapy for AML within 28 days prior to the study entry. Hydrea is permitted for the treatment of leukocytosis but must be stopped prior to starting study drugs.
- Female patients who are pregnant or breastfeeding.
- Concurrent treatment with other anti-cancer therapy except adjuvant antihormonal agents for breast cancer or for limited stage prostate cancer.
- Known infection with HIV.
- History of other active malignancy. Subjects who have been disease-free for 2 year or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
- FAB AML M1, 2, 6, 7 will be excluded if they do not have high eIF4E expression. AML M3 is always excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ribavirin, vismodegib, decitabine
Decitabine 20mg/m2 IV QD days -7 to -3 for cycle 1.
Ribavirin 1400mg BID and vismodegib 150mg QD starting on day 1.
On subsequent cycles, decitabine will be administered on days 1 to 5.
|
|
Experimental: Ribavirin, vismodegib
Ribavirin 1400mg BID, vismodegib 150mg QD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy will be measured by overall response rate (ORR).
Time Frame: Measured up to 2 years after the last subject has enrolled in the study.
|
Measured up to 2 years after the last subject has enrolled in the study.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to response
Time Frame: Measured up to 2 years after the last subject has enrolled in the study.
|
Measured up to 2 years after the last subject has enrolled in the study.
|
Duration of response
Time Frame: Measured up to 2 years after the last subject has enrolled in the study.
|
Measured up to 2 years after the last subject has enrolled in the study.
|
One year survival
Time Frame: Measured up to 2 years after the last subject has enrolled in the study.
|
Measured up to 2 years after the last subject has enrolled in the study.
|
Overall survival
Time Frame: Measured up to 3 years after the last subject has enrolled in the study.
|
Measured up to 3 years after the last subject has enrolled in the study.
|
Hematologic improvement defined by the number of individual, positively affected cell lines (erythroid, neutrophil and platelet cells) per patient.
Time Frame: Measured up to 2 years after the last subject has enrolled in the study.
|
Measured up to 2 years after the last subject has enrolled in the study.
|
Number of participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: Measured up to 2 years after the last subject has enrolled in the study.
|
Measured up to 2 years after the last subject has enrolled in the study.
|
Changes in eIF4E expression, localization, and signalling pathways (measured by immuno-histochemical analysis, PCR or western blot) and correlating with each patient's overall response.
Time Frame: Measured up to 2 years after the last subject has enrolled in the study.
|
Measured up to 2 years after the last subject has enrolled in the study.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sarit Assouline, MD, Jewish General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ribavirin=005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
Clinical Trials on Ribavirin
-
Institute of Liver and Biliary Sciences, IndiaTerminated
-
University of Roma La SapienzaCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Hoffmann-La RocheCompletedHealthy VolunteerMexico
-
University of BernRoche Pharma AG; University of Lausanne; University of Basel; Cantonal Hospital... and other collaboratorsCompleted
-
Janssen-Cilag International NVNo longer availableHepatitis CAustralia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
-
Conatus Pharmaceuticals Inc.Completed
-
National Institute of Diabetes and Digestive and...CompletedHepatitis C, ChronicUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedHEAD & NECK CancerUnited States
-
Kaohsiung Medical University Chung-Ho Memorial...Completed